



CINP

THE INTERNATIONAL COLLEGE OF
NEUROPSYCHOPHARMACOLOGY

**Biennial
Business
Report
2018 – 2020**

Table of Contents

President's Report	3
Treasurer's Report	5
Secretary's Report	6
Nominations Committee Report	7
Credential and Membership Committee Report	8
Fellowship and Awards Committee Report	
Pioneer Awards	9
Sumitomo/Sunovion Brain Health Basic Research Award	10
Sumitomo/Sunovion Clinical Health Basic Research Award	10
Ethics Prize	11
Max Hamilton Memorial Prize	11
Rafaelsen Young Investigators Awards	12
Student Encouragement Awards	14
Editor-in-Chief Report	16



President's Report

Professor Siegfried Kasper



As CINP President, it is my honour to report to you, the members of CINP, on our progress as a society over the past several years and our plans for the future. More than two years ago, I inherited the leadership of the society after several years under the highly capable stewardship of Professor John Krystal. I would like to thank

Professor Krystal for his insights and dedication to CINP, both during and after his term as president, and as he is now leaving the Executive Committee (EC) I wish him all the best in the future.

I quickly realized that ongoing important initiatives to improve CINP's finances needed to continue, while at the same time I knew we would face new challenges requiring new solutions. Below is a summary of what I feel have been our key accomplishments.

A. CINP Management and Governance

As the international society to promote the study, teaching, and application of neuropsychopharmacology, the crucial work of CINP requires thousands of hours of effort behind the scenes each year by volunteers and our professional staff.

1. Safeguarding CINP through difficult times

At the beginning of my term as President in 2018, CINP embarked on a new chapter with the selection of ICS as the society's association and conference management company. We could not have known at that time the challenges that we and the world would face. The global COVID-19 pandemic led to the postponement of the 2020 World Congress and ultimately the transition to CINP's first-ever Virtual World Congress.

Over the course of inventing and reinventing ways to effectively respond to the changing and uncertain COVID-19 situation, the EC and I have come to rely heavily on our staff team, including Association Director Matt Riley, CAE, Association Manager Yannik Braemer, Congress Managers Marta Collins and Gertrud Jeewanjee, and the rest of the congress team focusing on marketing, registration, sponsorship, and now the new tasks of virtual video production and technology support. Although difficult, these challenges have shown us that we chose well indeed when we retained the services of ICS, which is why the EC

has approved a contract extension to keep the association management and conference management teams in place through 2022.

2. Creating CINP's first Virtual World Congress

With the support of my esteemed colleagues on the EC and our professional staff, we have created a groundbreaking new event that will enable the global neuropsychopharmacology community to connect and share the latest knowledge in the field in a safe and effective way. While this kind of virtual event will be new for all of us, I am confident that CINP members will embrace the concept and even find new value in the experience.

While we hope that circumstances will have improved enough by November 2021 for us to host the 2021 World Congress in Montreal in person, we have also established the platform, technologies, and processes in such a way that they can be called upon again in the future if needed.

3. Ensuring the Long-Term Financial Viability of CINP

Even before the pandemic, CINP had taken certain actions to address deficit spending that had begun to draw down the society's reserves, largely because of reduced industry support over time and intermittent congress revenue. The society had begun to put measures in place to ensure its long-term viability, including reducing general expenses and making the World Congress an annual (instead of semi-annual) event. Unfortunately, the pandemic interfered with what would have been the first annual congress and forced us to focus more on short term changes.

With the loss of the congress revenue, 2020 was bound to be a bad year financially for CINP, but we have taken several key actions to minimize reserve spending, including: 1. Launching new live webinars and a virtual library; 2. Working with ICS to make temporary reductions to our management contracts; and 3. Tightly controlling all other expenses.

With uncertainty continuing into 2021 and more long-term work still to be done to ensure steady and diversified revenue streams coming into CINP to fund our operations, this will be a key area of focus going forward.

4. Revising the CINP Constitution and Bylaws

As the longest-established organization of its kind, CINP has an ongoing need to review our foundational Constitution and Bylaws to ensure that they are aligned with the society's long-term mission and the changing landscape of our field. I would

President's Report

like to thank Professor Krystal for leading a review of these documents in 2020, as well as the EC and CINF members who voted to approve the recommendations. This ensures that these documents will serve CINF well going forward, as we continue to review them every 3-5 years.

B. CINF Objectives

Beyond managing its day-to-day operations and governance, CINF has important scientific and administrative goals that serve our greater mission. I would like to highlight a few areas of continuing focus for the society:

1. Fostering the global scientific community

CINF events (both in person and virtual) represent the most important way for the neuropsychopharmacology community to share new research findings, learn about new developments, and build friendships and collaborations around the world. In addition to supporting and collaborating with well-established regional partner societies including ACNP, ASCNP, and ECNP, CINF is also committed to providing educational events and opportunities to developing nations. In recent years, this has included hosting events in Ibadan, Nigeria; Eldoret, Kenya; Kolkata, India and others. We hope that our financial efforts will ultimately generate more funding that we can devote to this important work.

2. Encouraging diversity in neuropsychopharmacology

We know inherently as scientists that diversity of backgrounds can help to balance biases, ensure that questions are considered from every angle, and ultimately result in the best outcomes. For that reason and many others, I am proud of CINF's commitment to promote diversity in terms of race, age, gender, sexual orientation, disability, philosophical and religious beliefs, cultural background, health status, and language.

The Diversity Task Force, led by Professor Jayashri Kulkarni is constantly working to increase diversity among the CINF membership and leadership, and the new 2021-2023 CINF EC will enjoy greater diversity. But we cannot fully accomplish this goal without your help and support. Please take a moment to consider a nominee for a CINF award who might have been overlooked, a student or young scientist who may need a mentor, or a diverse candidate deserving of nomination for a CINF leadership position. There is more that we can and should do in this area, and I know that this will continue to be a priority for CINF going forward.

C. Expressions of gratitude and congratulations

In addition to those that I thanked earlier, I would like to thank my fellow CINF members for giving me the opportunity to lead this wonderful society. I also warmly thank the CINF association and conference staff for their invaluable assistance, as without their hard work our accomplishments as a society would not have been possible. I would also like to express my deepest gratitude to the members of the CINF EC for their dedicated service, including Past President John Krystal, President-Elect Pierre Blier, Vice Presidents Joseph Zohar and Shih-Ku Lin, Secretary Elias Eriksson, and Treasurer Kazutaka Ikeda as well as our CINF Councilors.

I congratulate the following individuals for their election to CINF Office from 2021 onwards: Joseph Zohar (President Elect); Maria Oquendo (Vice President); Kazutaka Ikeda (Treasurer); Gabriella Gobbi (Secretary); and Noboru Hiroi, Ming-Chyi Huang, Carlos Zarate, and Tian Mei Si (Councilors). I am also honored to remain on the EC as Immediate Past President.

Lastly, I congratulate CINF members for their wisdom in electing Pierre Blier to be CINF's new president. I have greatly valued his collaboration and I am pleased to pass the role on to such an accomplished leader. Although the past year has been challenging and many of those challenges will continue to be present for the foreseeable future, I see great things ahead for CINF.

Sincerely,



Professor Siegfried Kasper

Treasurer's Report

Prof. Kazutaka Ikeda, Japan



Thank you very much to the CINP membership for electing and giving me the trust to act as the CINP treasurer for this four-year term. During the first two years of my term, I faced a critical time for the college as the pandemic affected not only the CINP World Congress, but also the overall finances of the college. Therefore, together with the CINP Executive Committee, I

took several measures in order to ensure a long-term financial stability of the CINP.

The first decision we made during the Executive Committee meeting in December 2019 was to move two investment funds which are managed by Kleinwort Hambros in London, UK, from a high-risk portfolio into a medium risk portfolio. Therefore, all the three funds are now invested in the medium risk portfolio which decreases the overall volatility. This decision was very well timed as the economy was tremendously impacted by the pandemic in March was also affected our funds of course, but the extent of the impact decreased with the change to a medium risk portfolio.

As the congress last year, which was originally scheduled for June 2020, was postponed to a virtual congress for February 2021, we reached out to the International Convention Centre in Taipei, Taiwan and agreed on a postponement of the contract to 2022. This was the first big step to reduce the expenses in 2020. Moreover, our management company ICS was willing to offer a management package for the work done for the in-person congress as well as the organization for the virtual congress for which I would like to sincerely thank them. This further reduced our budgeted expenses to a minimum.

Additionally, the expenses and income of the college were thoroughly reviewed in order to ensure an increase in the income and to contain the expenses. Therefore, the EC took several action steps to decrease the expenses and found additional revenue streams like the small webinar series to increase the revenue of the college. With the annual World Congress which would normally take place without a pandemic, additional income will be generated which allows CINP to further contribute to the field of neuropsychopharmacology.

Lastly, I would like to express my gratitude to the CINP Head Office for their assistance during the last two years by managing the financial side of things within the college efficiently and effectively. I would also like to thank Fiona Struthers from AD+ for her role in auditing the financial

activities of the society and providing excellent advice on how we manage risk. Finally, I would like to thank CINP President Prof. Siegfried Kasper and the members of EC and Finance and Budget Committee for the fruitful collaboration and to ensure operating with a high level of fiscal responsibility.

In the following you will find the 2020 Accounts which have been prepared together with the CINP Head Office. As the past year just ended, these figures are to be audited by Fiona Struthers and AD+ which could result in some minor changes.

It has been a pleasure to serve as the CINP Treasurer for the past years and look forward to doing so in the next years in order ensure a long-term financial viability of the college and to continue its important contributions to the field of neuropsychopharmacology.

	2019 Funds	2020 Projected Funds*
Projected Income & Endowments		
Charitable Activities		
Membership Dues	\$50,238	\$56,912
Congress Income	\$397,889	-
Journal Income	\$151,503	\$49,422
Education Activity Income	-	\$7,597
Total Income	\$599,630	\$113,931
Projected Expenditure		
Charitable Activities		
Congress Expenditure	\$422,671	-
Charitable Expenditure	\$498,604	\$472,801
Total Expenditure	\$921,275	\$472,801
Projected Net incoming / (outgoing) resources	\$ (321,645)	\$ (358,870)

*2020 Projected Funds subject to audit

Secretary's Report

Prof. Elias Eriksson, Sweden



While the Executive Committee (EC) held its meetings as planned during the second half of 2018 and 2019, we unfortunately were not able to meet in-person anymore when the pandemic hit Europe in the beginning of 2020. However, under the leadership of the C-INP President, several online meetings were held in

2020 in order to safeguard C-INP through these difficult times. The EC thus met virtually almost monthly during this period to discuss, e.g., how to proceed with the 2020 C-INP World Congress, which led to this congress being transformed into the Virtual 2021 World Congress. Among other items discussed were the implementation of C-INP webinars, how to increase C-INP membership, venues for future World Congresses, and the election of recipients for the different C-INP awards.

The members of the Executive Committee have met on a regular basis as follows:

June 2018 – Vienna, Austria:

In conjunction with the C-INP biennial World Congress in Vienna, the EC and C-INP Councils were introduced to representatives from the International Conference Services Ltd. (ICS) which had been hired to take care of the C-INP management and to be in charge of the new C-INP Head Office.

December 2018 – Hollywood, Florida:

An important decision taken at the EC meeting held during the ACNP Annual Meeting was that the C-INP World Congress in the future will be annual rather than biannual.

March 2019 – Taipei, Taiwan:

In conjunction with the meeting of the International Scientific Program Committee (ISPC) for the 2020 C-INP World Congress originally planned to be held in Taipei, Taiwan, the EC met to go through the program once more and to discuss other items concerning the general business of the college.

October 2019 – Athens, Greece:

During the successful 2019 International Meeting in Athens, the EC met to evaluate this meeting and to discuss various upcoming tasks.

December 2019 – Orlando, Florida:

In conjunction with the ACNP Annual Meeting, the EC had its last in person meeting prior to the outbreak of the pandemic.

Online Meetings 2020:

Throughout 2020, the EC met several times online to maneuver the college through the difficulties caused by the pandemic. The decision to go virtual with the 32nd C-INP World Congress, as well as to reshuffle the destinations for the future World Congresses, were made.

One important development for C-INP during the past years has been a very encouraging increase in the interest in the College from several Asian countries manifested in the form of many new members and high attendances at C-INP activities from this part of the world. For the forthcoming years, the College – the only global platform for psychopharmacology – must strive for a similar development also in other parts of the world. While the pivotal decision to arrange annual World Congresses should markedly aid this endeavor, it will also be important to make these congresses attractive both for active researchers wanting to exchange views and recent data and for clinicians wanting an update in relevant fields of psychopharmacology.

Another important development forced upon the C-INP as a result of the pandemic, as it has been forced upon other similar societies, is the utilization of virtual alternatives to IRL congresses and educational activities. While we all look forward to when we will be able to meet again in person, which will hopefully be in Montreal in November this year, there is no doubt that virtual alternatives for scientific exchange and education will play a prominent role for C-INP also in the post-pandemic future.

I have very much enjoyed my time as C-INP secretary and am confident that the incoming Secretary, Gabriella Gobbi, will prove to be an excellent successor for this position who will fulfill the secretary duties in an impeccable way. Lastly, I would like to thank the C-INP membership for giving me the opportunity to act as C-INP Secretary for the past 7 years and the C-INP Executive Committee and C-INP Head Office for a very fruitful and enjoyable collaboration. I wish the College best of luck for the future.

Nominations Committee Report

By Committee Chair

Dr. John Krystal



I would like to sincerely thank the members of this committee for their support in the past two years who helped with selecting the candidates for the voting by the CINP membership. In 2020, there were two vacant positions on the Executive Committee (President-Elect & Vice President) as well as three positions on the CINP Council.

Committee Members

- Bitu Moghaddam, USA
- Michael Davidson, Israel
- Rainer Rupprecht, Germany
- Shih-Ku Lin, Taiwan

Nominations by membership were received and reviewed by the Committee for each position. We took into consideration knowledge of CINP, contribution to CINP, gender, geographical spread, and scientific interests. After careful consideration by the Committee members, a slate of candidates was presented to the Executive Committee and finalized. Finally, all current CINP Members and Fellows were invited to vote for a candidate for each position.

After the first round of elections, Prof. Joseph Zohar was elected for President-Elect (current Vice President) for whom we had to find a replacement on the Executive Committee. In a second election round by the membership, Dr. Maria Oquendo was elected Vice President.

The online voting went smoothly, and, on behalf of the Nominating Committee, I hereby would like to present the names of those selected by the membership:

President-Elect (2021 – 2022): Joseph Zohar, Israel (M)
(President 2022 – 2024;
Past-President 2024 – 2026)

Vice President (2021 – 2024): Maria Oquendo, USA (F)

Councilors (2021 – 2024): Noboru Hiroi, USA (M)
Ming-Chyi Huang, Taiwan (F)
Carlos Zarate, USA (M)
Tian Mei Si, China (F)

Together with the new additions to the CINP Board, the new CINP Executive Committee and new Council consist of the following members:

CINP Executive Committee

- Pierre Blier, Canada (President, M)
- Siegfried Kasper, Austria (Past President, M)
- Joseph Zohar, Israel (President-Elect, M)
- Maria Oquendo, USA (Vice President, F)
- Shih-Ku Lin, Taiwan (Vice President, M)
- Kazutaka Ikeda (Treasurer, M)
- Gabriella Gobbi, Canada (Secretary, F)

CINP Council

- Allan Young, United Kingdom (M)
- Atsumi Nitta, Japan (F)
- Carlos Zarate, USA (M)
- Carol Tamminga, USA (F)
- Katharina Domschke, Germany (F)
- Ming-Chyi Huang, Taiwan (F)
- Noboru Hiroi, USA (M)
- Peter Falkai, Germany (M)
- Ryota Hashimoto, Japan (M)
- Tian Mei Si, China (F)

With the new newly elected officers we were able to improve the geographical as well as gender balance within the CINP Board.

I would like to take this opportunity to thank the members of the Nominating Committee for their support, the Executive Committee for their advice, the Central Office for carrying out the online voting and especially the CINP members who actively participated in the nomination and election process.

Credentials And Membership Report

By Committee Chair

Prof. Kazutaka Ikeda



I am very pleased to report that CINP's membership grew by 184 new members in 2019 and 2020, which is almost twice as much compared to the period before. The wide distribution of members across the world as well as the gender diversity underline that CINP is a truly global society.

I would like to sincerely thank the members of this committee for their support in the past years who continuously promoted the advantage of a CINP membership all over the globe.

- Elias Eriksson, Sweden
- Allan Young, UK
- Bitia Moghaddam, USA
- Jun Soo Kwon, Korea
- Rainer Rupprecht, Germany
- Yasumasa Okamoto, Japan

Below you can find an overview of countries of our new members and their membership level.

New Members by Country				New Members by Category	
Japan	43	Greece	2	Fellows	71
United States	34	Hong Kong	2	Members	73
Canada	14	Singapore	2	Associate Members	40
Taiwan	11	South Africa	2		
United Kingdom	8	United Arab Emirates	2		
Australia	7	Belgium	1		
Switzerland	6	Brazil	1		
Republic of Korea	5	Cambodia	1		
Sweden	5	Chile	1		
Argentina	3	Colombia	1		
Austria	3	Cyprus	1		
China	3	Indonesia	1		
India	3	Israel	1		
Italy	3	Norway	1		
Russia	3	Romania	1		
Turkey	3	Spain	1		
Denmark	2	Tanzania	1		
France	2	Thailand	1		
Germany	2	Ukraine	1	Total	184

Fellowship and Awards Committee Report

Pioneer Awards



Oleh Hornykiewicz

Oleh Hornykiewicz was born on November 17, 1926 in Sychiw near Lviv/Lemberg in Eastern Galicia today belonging to the western part of Ukraine and died on May 26, 2020. He received his M.D. degree from the University of Vienna and joined the faculty of his alma mater the same

year and has worked there ever since. He also served for twenty years as chairman of the Institute of Biochemical Pharmacology. In 1967, he began a long association with the University of Toronto in Canada and, in 1992, he was named professor emeritus at that institution.

One of his seminal accomplishments was the discovery that Parkinson's disease was due to dopamine deficiency in the brain. He also played a key role in the development of L-dopa as a therapy for the disorder.

After the integration of the Institute of Biochemical Pharmacology into the Brain Research Institute of the University of Vienna in 1999, he spent, up to three years ago, all days at his office at the Brain Research Institute, now Center for Brain Research of the Medical University of Vienna. An enthusiastic scholar, he vividly discussed his ideas on a variety of different topics in neuroscience. His favorite topic however still remained basal ganglia and Parkinson's disease.



Judith Rapoport

Dr. Judith Rapoport has concentrated her research on several aspects of child psychiatry, including diagnosis, childhood hyperactivity, pediatric psychopharmacology, and obsessive-compulsive disorder. Her current research on attention deficit hyperactivity disorder has

focused on normal and abnormal brain development. Dr. Rapoport was named chief of the Child Psychiatry Branch of the National Institute of Mental Health in 1984. In addition to her research at NIH, she is also a professor of psychiatry at George Washington University School of Medicine, and a clinical professor of psychiatry and pediatrics at Georgetown University Medical School.

Dr. Rapoport has authored and coauthored three professional books and over two hundred research journal articles. She also serves on the editorial board of *Advances in Clinical Child Psychiatry*, *American Journal of Psychiatry*, and *Journal of Child Psychology and Psychiatry*, among others. Among her many honors are several awards including the G. Burroughs Mider Lecture, NIH, in 1993, the American Psychiatric Association Award for Research in 1992, the Presidential Meritorious Executive Rank Award in 1991, and the NIMH Director's Award in 1990.



Torgny Svensson

Torgny Svensson, Professor emeritus of Pharmacology at Karolinska Institutet, succumbed to Covid-19 on Friday June 12, 2020, at the age of 75. He is grieved by his wife Louise and their children Martin, Jenny and Michael, and missed by many friends and colleagues in Sweden and around the world.

During Torgny's period as a very successful president of the Scandinavian College of Neuropsychopharmacology (SCNP) from 2001 to 2005, the annual meetings of this society attracted more attendants than ever before. Illustrating his standing in the international psychopharmacological sphere, he became President of the CINP in 2006, and held this position when the society celebrated its 50 years anniversary. Torgny was a person whom you did not easily forget, if you had the privilege to meet him on a person-to-person basis. He was a great scientist always ready to discuss experiments and his most novel ideas in detail, and he inspired and guided a large number of PhD students through their journey to a successful defense.

Fellowship and Awards Committee Report

Sumitomo/Sunovion Brain Health Basic Research Award



Tibor Harkany

Dr. Tibor Harkany is Professor at the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden and Chair of the Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Austria.

He is one of the world's leading neurobiologists to study the developmental consequences of maternal drug abuse during pregnancy, with a keen focus on cannabis and psychostimulants. His work on the molecular basis of how $\Delta 9$ -tetrahydrocannabinol (THC) impacts brain development and imposes life-long modifications to the cortical circuitry is particularly honored by this award.

Dr. Harkany's early contributions addressed the developmental dynamics of endocannabinoid signalling; particularly showing that endocannabinoid action on cannabinoid receptors affects neuronal migration and differentiation in the cerebral cortex (PNAS, 2005/2008; J Neurosci 2010; Nat Commun 2014). He has demonstrated that endocannabinoids act as repulsive cues for directional axonal growth, thus being important to shape neuronal connectivity in the developing brain (Science, 2007). He then applied this knowledge to identify the nascent axon as the compartment foremost affected by THC action and described the molecular mechanism by which THC impairs cytoskeletal dynamics to inhibit axonal growth (EMBOJ, 2014).

Sumitomo/Sunovion Clinical Health Basic Research Award



Gustavo Turecki

Dr. Gustavo Turecki's research focuses on understanding the molecular changes that occur in the brains of individuals who feel so hopeless and depressed that they see suicide as the only way out. Gustavo's multidisciplinary career has focused on both the influence of life events of the

risk of depression, suicide, and suicidal behaviour, and on the epigenetic control of brain function and development. He regularly publishes his work in the highest-ranked journals, including 20 articles in Nature and sister journals such as Nature Neuroscience, all since 2007. His productivity has earned him an h-index of 98, and his nearly 500 publications have collectively been cited over 36,000 times.

Gustavo is a recognized leader in the molecular and genomic aspects of suicide and depression. He is regularly invited to contribute review articles and position papers for leading clinical and scientific journals. These reviews, such as the ones published in Trends in Neuroscience (2012), Nature Neuroscience Reviews (2014), Molecular Psychiatry (2017), and Nature Reviews Disease Primers (2019) allow researchers to stay informed of recent molecular and biological advances related to suicide.

Fellowship and Awards Committee Report

Ethics Prize



Paul Appelbaum

For the last decade, Dr. Paul Appelbaum has headed an NIH-funded center for studies of ethical, legal and social issues in neuropsychiatric and behavioral genetics at Columbia. He has identified many of the ethical challenges associated with advances in psychiatric

genetics, the ethics and effects of research on genetic bases for addictions, the preferences of people with disabilities (including psychiatric disabilities) regarding inclusion in genomic research, and popular understandings of the genetic bases of antisocial behavior. He co-lead a project on the ethics of genetic research on intelligence, and has written on return of research results, informed consent and other aspects of genetic research.

Dr. Appelbaum's prominence as a psychiatric ethicist has been recognized with his appointments as chair of the APA's Ethics Review Board, the WPA's Standing Committee on Ethics, and the ACNP Ethics Committee. He has received AMA's Award for Leadership in Medical Ethics and Professionalism, and a Special Presidential Commendation from the APA for his ethics leadership. His contributions have led to his election to the U.S. National Academy of Medicine and numerous named lectureships in medical ethics.

Max Hamilton Memorial Prize



Mu-Hong Chen

Dr. Mu-Hong Chen, M.D., Ph.D. graduated from Department of Medicine, National Yang-Ming University, Taiwan in 2006 and received his general psychiatric training between 2009 and 2013 and completed his child and adolescent psychiatric training in 2014.

His research career began in the first year (2009) of the resident training course and joined and completed the rTMS/TBS (theta burst stimulation) clinical trials (as the second author) for treatment-resistant depression (TRD) under Prof Tung-Ping Su's and Prof Cheng Ta Li's instructions. For Dr Chen's diligent work, he received WFSBP poster travel award in 2013, Taiwan- Japanese Young Scientist Award in 2014 and 2015, and Outstanding Research Award and Excellent Research Award for Asian College of Neuropsychopharmacology 2019. Dr Chen is also an enthusiastic teacher, and he received the Clinical Teaching Excellence Physician Award, 2016, Taipei Veterans General Hospital.

Finally, Dr Chen is also a poet, won several literary awards and published three works of poetry, including Sailor's diary, Quietness, and Gods and Monsters. He also works hard in LGBT mental health and promotes the LGBT psychoeducation for the medical students and psychiatrists.

Fellowship and Awards Committee Report

Rafaelsen Young Investigators Awards



Lucie Bartova

Dr. Lucie Bartova, born in Ostrava, Czech Republic, obtained her medical degree (MD) in 2012 at the Medical University of Vienna (MUV) in Austria. As a diploma and subsequently doctoral student at the Department of Psychiatry and Psychotherapy of the MUV,

she investigated neuroimaging correlates of acute and remitted major depressive disorder (MDD) and obtained her scientific degree (PhD) in 2019. Simultaneously, she completed her psychotherapeutic training and residency in psychiatry, whereby she has been involved in clinical, psychopharmacotherapeutic and neuroimaging studies focusing predominantly on MDD and schizophrenia. In the past years, Dr. Lucie Bartova has increasingly focused on challenging psychiatric conditions such as treatment resistant depression (TRD). She presented her work at national and international conferences which could be published in known psychiatric journals, received performance scholarship of the MUV as well as travel- and research awards, and served as a member of the Scientific Programme & Local Organising Committee for the CINP Thematic Meeting 2017 in Prague, Czech Republic on the topic of TRD.




Chandni Hindocha

Dr Chandni Hindocha graduated with a PhD in Psychopharmacology in 2018 from University College London (UCL). Her research focuses on the behavioural, neuroimaging and genetic risk factors that lead people to experience the acute and chronic effects of cannabis.

She has 35 publications of which 15 are first-author papers. She has a strong background in clinical trials of highly-regulated investigative medicinal products, experimental

and translational medicine using both longitudinal and cross-sectional research. Chandni is currently a post-doctoral research fellow at the Clinical Psychopharmacology Unit and the Translational Psychiatry Research Group, University College London.



Millie Rincón-Cortés

Millie Rincón-Cortés, PhD, is a Postdoctoral Research Associate in the laboratory of Dr. Anthony Grace at the University of Pittsburg. Here, she has been funded through a T32 Training for Transformative Discovery in Psychiatry Fellowship, an F32 Individual Postdoctoral Fellowship

from the National Institute of Mental Health (NIMH) to study stress-induced dopamine downregulation in rats and how these effects may differ between the sexes, and a Ford Foundation Postdoctoral Fellowship to study how adverse postpartum environments influence maternal brain and behavior. Prior to joining the Grace lab, she received her B.S. in Biology from the University of Puerto Rico-Mayaguez (2009) before completing a PhD in Neuroscience and Physiology at the NYU Medical Center's Sacker Institute for Graduate Biomedical Sciences (2015). Her dissertation work was conducted under the supervision of Dr. Regina Sullivan and funded by a National Science Foundation (NSF) Graduate Research Fellowship. Dr. Rincón-Cortés was awarded the Sackler Dissertation Prize by the NYU School of Medicine and the Dissertation Award by the International Society for Developmental Psychobiology (ISDP) for this work.

Fellowship and Awards Committee Report

Rafaelsen Young Investigators Awards (ctd)



Zachary Gerring

Zachary Gerring is a human geneticist specialising in the statistical analysis of common complex traits. His expertise spans statistical genetic and genomic analysis, epidemiology, bioinformatics and biostatistics. Zac is a postdoctoral fellow at the Queensland Institute of

Medical Research Berghofer (QIMRB) in Australia, where, as a member of the psychiatric genomics consortium, he has made a substantial contribution to the functional analysis of neuropsychiatric disorders. Most notably, he developed a gene co-expression network-based analytical approach for the functional interpretation of genome-wide association data, as well as a gene-based method for the identification of candidate causal genes underlying complex traits. Zac is currently working on the integration of gene co-expression network data with a large database of drug-gene signatures to identify drug compounds that target dysfunctional mechanisms underlying Alzheimer's disease.



Pia Baldinger-Melich

After receiving her doctoral degree in 2009 (M.D.), Pia Baldinger-Melich joined the Neuroimaging Lab at the Department of Psychiatry and Psychotherapy at the Medical University of Vienna in April 2010 and was involved in the planning and implementation

of several neuroimaging studies (using PET and MRI), especially with regard to mood and anxiety disorders. In 2015 she successfully completed the doctoral program "Clinical Neuroscience" (PhD) in the field of imaging genetics. In 2016 she became an Assistant Professor and has since then dedicated her work on the search for imaging markers of depression and antidepressant treatments, including

electroconvulsive therapy. Since 2018 Pia Baldinger-Melich is a senior physician at the Intermediate Care Unit of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna.



Giselli Scaini

Giselli Scaini received her PharmD degree (2008), a master's degree (2010), and her PhD (2014), in Health Science from the University of Southern Santa Catarina (UNESC, Brazil). Currently, she is an instructor at the Faillace

Department of Psychiatry and Behavioral Sciences and a translational researcher in the field of biological psychiatry. Scaini's translational research is focused on understanding the complex interactions between molecular and cellular mechanisms and cognitive impairment, behavioral, and neuroanatomical changes in psychiatry disorders, especially in mood disorders.



Hon-Cheon So

Hon-Cheon So is a physician-scientist who was trained in both clinical medicine and statistical genomics. He was enrolled in the first intercalated MBBS-PhD program in Hong Kong and received his graduate education in statistical and psychiatric genomics.

His main research interest lies in the development and applications of statistical and computational methodologies in analyzing "omics" and clinical data, with a special interest in psychiatry. For example, together with colleagues, they have developed methods to decipher the genetic architecture of complex diseases, performed risk prediction and subtyping of psychiatric disorders by both clinical and genomic data, and repositioned existing drug for new indications in psychiatry. The over-arching goal is to translate genomics findings into clinical practice, with the hope to improve diagnosis and treatment of complex diseases.

Fellowship and Awards Committee Report

Student Encouragement Awards



Yui Asaoka
Japan



Cassandra Jay Hatzipantelis
Australia




Yee-Lam Elim Chan
Taiwan



Mao-Hsuan Huang
Taiwan



Chun-Hung Chang
Taiwan




Arkadiusz Komorowski
Austria



Hsuan-Te Chu
Taiwan



Aika Kosuge
Japan



Tomonori Hara
Japan



Hisayoshi Kubota
Japan

Fellowship and Awards Committee Report

Student Encouragement Awards (ctd)



Shunya Kurokawa
Japan



Youge Qu
Japan



Yuka Kusui
Japan



Joep Titulaer
Sweden



Chi-Wei Lee
Taiwan



Shih-Chun Wan
Taiwan



Da-Zhong Luo
Taiwan



Siming Wang
Japan



Hajime Miyanishi
Japan



Ana Weidenauer
Austria

Editor-in-Chief Report

Anthony A. Grace



I am pleased to present an update of the activities of the IJNP in 2020-2021. In July of 2020 I became the Editor-in-Chief of the journal, following in the footsteps of Alan Frazer, who did an outstanding job as the previous Editor-in-Chief. After a brief dip due to the move to Open Access, our Impact Factor has increased from 4.207 to 4.333

for 2019. We expect this to increase further as the number of quality submissions increases. We are also receiving a higher proportion of clinical manuscripts, which tend to be cited more often.

We currently have 52 members on our editorial board and, appropriately for an international journal, there is a broad geographical distribution: 24 from Europe; 20 from North American; 3 from Asia and Australia, and 5 from South America.

We had a virtual Field Editors' retreat in November 2020, where we announced the changes in makeup of our Field Editors and Editorial Board. We went from 7 Field Editors to 5 Field Editors because of budget constraints and to distribute the workload more equitably. We have added two new Field Editors, giving us a gender balance of 2 females and 3 males:

- Michael Thase (Clinical)
- David Morilak (Preclinical)

Three previous field editors term ended:

- Anthony Grace (now EIC)
- Pierre Blier (previously Translational Field Editor)
- Siegfried Kasper (previously Reviews Field Editor)

In order to fill out expertise in needed areas and to eliminate nonresponsive reviewers, the editorial board made the following changes:

Editorial board members term ended:

- Brian Dean (Victoria, Australia)
- Klaus Peter Ebmeier (Oxford, UK) - Resigned
- Astrid Linthorst (Bristol, UK)
- Falk Lohoff (Bethesda, USA)
- Eva Meisenzahl (Düsseldorf, Germany)
- David Morilak (San Antonio, USA) - Field Editor
- Norio Ozaki (Nagoya, Japan)
- Rainer Spanagel (Mannheim, Germany)
- Michael Thase (Pittsburgh, USA) - Field Editor
- Mauricio Tohen (Albuquerque, USA)

This provides us with a total membership of 52, with 22 Female Members: (42%). We will have a virtual Editorial Board meeting on March 17, 2021.

In 2020, the geographical distribution of authors of published articles was 30% from Europe, 31% from North America, 32% from Asia, 2% from Australia and New Zealand, 3% from Latin and South America, and 2% from the Middle East and Africa. Views of articles on our webpage have continued to increase, moving from 52,656 for a monthly average in 2019 to 55,171 in 2020.

In order to disseminate information regarding a broader scope of our journal and to attract more high-impact papers in areas such as neurology, we decided to add a tagline that will be implemented soon and added to our cover: Translational Research into Brain Function and Disease. This is currently on our journal web page.

In consultation with the Field Editors, Alan Frazer and myself chose the following two papers for the IJNP award for most cited papers in 2018-2019:

Clinical

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines - Konstantinos N. Fountoulakis, Grunze, Heinz; Vieta, Eduard; Young, Allan; Yatham, Lakshmi; Blier, Pierre; Kasper, Siegfried; Möller, Hans-Jürgen:

Preclinical

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine - Chao Dong, Zhang, Ji-Chun; Yao, Wei; Ren, Qian; Ma, Min; Yang, Chun; Chaki, Shigeyuki; Hashimoto, Kenji

Another piece of good news is that the Journal continues to contribute revenue for the College. Revenue for the Journal in 2020 was \$247,812 with the College receiving a percentage of the earnings.

In addition to the Editorial Board members, I would like to take the opportunity to thank the many people who make the production of IJNP possible, in particular the Field Editors, my Editorial Assistant, Ann Miller, and Matt Turney, who manage the Journal for Oxford University Press (OUP), and the entire marketing and production team at OUP. And in particular Alan Frazer, through whose guidance the journal has become the stellar contribution that it is today.

#CINP2021



33rd CINP World Congress
of Neuropsychopharmacology
1 – 4 November 2021 Montreal, Canada

SAVE THE DATE





CINP Head Office

Gonzagagasse 17
1010 Vienna
Austria

Phone: +43 660 1258 463
Fax: +1 604 681 1049
info@cinp.org | www.cinp.org

For further information on CINP and to keep up to date with all
CINP activities please visit www.cinp.org